10-QPeriod: Q1 FY2003

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2003

Filed May 15, 2003For Securities:BIIB

Summary

IDEC Pharmaceuticals Corporation reported strong revenue growth and increased net income for the first quarter ended March 31, 2003, compared to the prior year. Total revenues surged by approximately 47% to $117.2 million, primarily driven by a significant increase in 'Revenues from unconsolidated joint business,' largely attributable to their Rituxan copromotion with Genentech. Net income rose by over 38% to $41.2 million, with diluted earnings per share improving to $0.24 from $0.17 in the prior year's quarter. The company also saw a substantial increase in operating expenses, particularly in research and development and selling, general, and administrative costs, reflecting ongoing investment in product development and commercialization efforts. Despite increased operating expenses and significant investments in manufacturing facilities, the company maintained a healthy cash position, with cash, cash equivalents, and securities available for sale totaling $1.5 billion.

Key Highlights

  • 1Total revenues increased by 47% to $117.2 million for Q1 2003, up from $79.7 million in Q1 2002.
  • 2Net income grew by 38.8% to $41.2 million in Q1 2003, compared to $29.7 million in Q1 2002.
  • 3Diluted Earnings Per Share (EPS) improved to $0.24 in Q1 2003, from $0.17 in Q1 2002.
  • 4Revenues from unconsolidated joint business, primarily related to Rituxan, rose significantly by 41.8% to $110.9 million.
  • 5Product sales of Zevalin reached $5.7 million in Q1 2003, marking the company's first product sales revenue from Zevalin.
  • 6Research and Development expenses increased by 52.9% to $29.4 million, reflecting investment in ongoing clinical development and a new collaboration with Biogen.
  • 7The company's cash, cash equivalents, and securities available for sale stood at $1.5 billion as of March 31, 2003, indicating a strong liquidity position.

Frequently Asked Questions

The primary driver of IDEC Pharmaceuticals' revenue growth was a significant increase in 'Revenues from unconsolidated joint business,' which includes their share of pretax copromotion profits from Rituxan with Genentech, reimbursement of expenses, and royalty revenue from Rituxan sales outside the U.S. This category saw a substantial increase of approximately 41.8% compared to the prior year's quarter.

Operating expenses increased significantly in the first quarter of 2003. Research and Development expenses rose by 52.9% to $29.4 million, primarily due to increased personnel, facility, and contract research expenses, including costs associated with a new collaboration with Biogen. Selling, General, and Administrative expenses also increased by approximately 27.2% to $23.9 million, supporting the commercialization of Zevalin and overall organizational growth.

IDEC Pharmaceuticals maintained a strong financial position with substantial liquidity. As of March 31, 2003, the company reported $1.5 billion in cash, cash equivalents, and securities available for sale, an increase from $1.4 billion at the end of 2002. This robust liquidity is expected to fund current and planned operating requirements.

The company highlights several key risks and uncertainties, including a heavy reliance on Rituxan sales for revenue, the need for successful commercialization of Zevalin in the U.S. and Europe, potential challenges in developing and commercializing new products, dependence on contract manufacturers and limited suppliers, limited sales and marketing experience, fluctuations in operating results, uncertainties regarding healthcare reimbursement, uncertain clinical trial outcomes, intense industry competition, and intellectual property and patent litigation risks, particularly concerning Zevalin.